Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing products and treatments that will benefit patients around the world. And from specialized efforts in biosimilars and rare disease to oncology and vaccines, we are committed to developing medical solutions that will matter most to the people we serve.

Key Innovative Programs in Registration / Phase 3

Key Biosimilars Programs in Registration / Phase 3

Key Programs in Phase 2

Pipeline date and pdf

Pipeline Snapshot as of January 29, 2019

Download Complete Pipeline PDF

Discovery Projects
Phase 1

35
Phase 2

28
Phase 3

26
Registration

11
Total100

Compound Name	Indication	Phase	Submission Type	Compound Type
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRD Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Respiratory Syncytial Virus Infection	Phase 1	New Molecular Entity	Vaccine
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Pfizer Innovative Medicines Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections (BREAKTHROUGH) Project advanced	Phase 3	New Molecular Entity	Vaccine
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRD Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Serogroups ABCWY meningococcal infections	Phase 1	New Molecular Entity	Vaccine
PF-06753512 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRD Mechanism of Action: Therapeutic Vaccine Go to clinical trial	Prostate Cancer	Phase 1	New Molecular Entity	Vaccine
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Pfizer Innovative Medicines Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Primary clostridium difficile infection (FAST TRACK)	Phase 3	New Molecular Entity	Vaccine
PF-06936308 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRD Mechanism of Action: Therapeutic Vaccine Go to clinical trial	Multiple Cancers Project advanced	Phase 1	New Molecular Entity	Vaccine
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRD Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections	Phase 2	New Molecular Entity	Vaccine
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRD Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive Group B streptococcus infection	Phase 1	New Molecular Entity	Vaccine
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ talazoparib (MDV3800) for: Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic)	Phase 2	Product Enhancement	Biologic
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Pfizer Innovative Medicines Mechanism of Action: Androgen receptor inhibitor Go to clinical trial	Non-metastatic High Risk Hormone Sensitive Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ PF-04518600 (OX40) for: Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck (Biologic)	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (BREAKTHROUGH)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Urothelial Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Gastric Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	1st Line Non-Small Cell Lung Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ PF-04518600 (OX40) and PF-05082566 (4-1BB) for: Cancer (Biologic)	Phase 1	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Pfizer Innovative Medicines Mechanism of Action: Anti PD-L1 Inhibitor Go to clinical trial	Combo w/ talazoparib (MDV3800) and Array's MEK inhibitor for: Solid Tumors (Biologic)	Phase 1	Product Enhancement	Biologic